Unitree IPO Oversubscribed 8,000 Times: What the Numbers…

The Unitree IPO is heavily oversubscribed on a scale that stands out even among high-profile technology listings. According to the company, Chinese retail investors requested more than 8,000 times the number of shares initially available to them. The reported final allocation rate was only about 0.018%. That is a powerful signal of market enthusiasm, but it does not prove that the shares are attractive at any price.

Key takeaways

Unitree is offering roughly 40.45 million new shares on Shanghai’s STAR Market.
The issue price is RMB 150.80 per share.
That implies gross proceeds of about RMB 6.1 billion and a valuation close to RMB 61 billion.
The retail tranche was reportedly more than 8,000 times oversubscribed; the final online allocation rate was about 0.018%.
Unitree is growing rapidly and is profitable, but the offer price implies demanding revenue and earnings multiples.

Why 8,000 times and 0.018% measure different things

The headline and the allocation rate appear inconsistent at first. A 0.018% rate mathematically corresponds to about one allocation for every 5,556 units requested, not one in 8,000. The likely explanation is a difference in denominators: oversubscription may refer to the retail shares initially reserved, while the final success rate can reflect shares reallocated between institutional and public tranches. Until a complete final allotment filing is available, the two figures should be treated as snapshots of different stages rather than identical metrics.

Oversubscription measures demand, not intrinsic value. In Chinese IPOs, investors may request far more shares than they can realistically receive. A very low allotment probability generates attention, but it says little about whether the post-listing price will remain sustainable.

The IPO numbers

Metric	Value	Context
Issue price	RMB 150.80	Set following institutional price consultation.
New shares	about 40.45 million	Approximately 10% of enlarged share capital.
Gross proceeds	about RMB 6.1 billion	Price multiplied by new shares, before costs.
Valuation	over RMB 60 billion	Approximately €7.7 billion using the conversion in the supplied report.
Retail allocation rate	about 0.018%	An exceptionally low probability in the online tranche.

Unitree’s draft prospectus originally identified RMB 4.202 billion in intended fundraising. The higher estimated gross proceeds of approximately RMB 6.1 billion follow from the subsequently determined offer price. Exchange documents say the capital will fund robot-model research, hardware platforms, new products and manufacturing capacity.

Growth and profit: strong but not straightforward

Revenue increased from roughly RMB 159 million in 2023 to about RMB 1.7 billion in 2025. Unitree reported 2025 adjusted profit, or profit excluding non-recurring items, of around RMB 590–600 million. Reported net profit attributable to shareholders was much lower at approximately RMB 278 million, partly because of share-based compensation and other non-recurring accounting items.

The latest quarter also warrants caution. Prospectus data indicate first-quarter 2026 revenue rose 69% to roughly RMB 420 million, while net profit fell 53% to about RMB 40 million. A fast-growing market does not guarantee steadily expanding margins.

Unitree says it shipped more than 5,500 humanoid robots in 2025. Market studies rank Unitree and AgiBot differently depending on definitions of shipment, robot size and product class. The volume is meaningful, but it should not be presented as a definitive global market share without the methodology. Our Unitree profile in the Robotics Atlas provides additional company and product data.

How demanding is the valuation?

Public figures allow a useful approximation. A valuation of around RMB 61 billion equals roughly 36 times 2025 revenue. Against reported net profit of about RMB 278 million, the implied price-to-earnings ratio is approximately 219. Even using the higher adjusted profit, the multiple would still be around 103.

These calculations are not a share-price forecast. They illustrate how much future growth is already embedded in the offering price. Investors are paying not only for current robot sales but for the expectation that Unitree can scale manufacturing, software and commercial deployment dramatically.

Why investors are excited

Technical position: Unitree built years of experience in quadruped robots and is extending that platform into humanoids.
Manufacturing ecosystem: China’s electronics supply chain may support rapid cost reduction and higher volumes.
Existing revenue: Unlike many robotics start-ups, Unitree already generates substantial sales and positive earnings.
Capital for scale: IPO proceeds are earmarked for models, robot hardware, product development and new manufacturing.

Risks investors should not ignore

Valuation risk: At high multiples, even modest disappointments in growth or margins can trigger sharp repricing.
Commercialisation risk: Research and demonstration shipments do not automatically translate into profitable industrial fleets.
Competition: AgiBot, UBTECH, Tesla, Figure, Boston Dynamics and many others are investing aggressively.
Geopolitics: New US restrictions on foreign humanoid and quadruped robots reduce access to a major future market.
International access: A STAR Market listing does not mean the stock will immediately be available through every European broker.

Assessment: demand is not the same as return

The extreme oversubscription turns Unitree into a symbol of China’s robotics boom. It shows that investors expect enormous growth in embodied AI. For long-term value, however, revenue quality, margins, customer mix, recurring software income, capital requirements and export access matter more than the number of subscription orders.

The IPO is a milestone for robotics, but it is not a risk-free entry point. Investors following the company should give more weight to its first published results as a listed business than to first-day trading. Our background article on Unitree’s rise in humanoid robotics explores the longer-term industrial context.

Sources and transparency

n-tv / Reuters: Unitree retail demand exceeds 8,000 times the available tranche, 11 August 2026 – supplied source.
Reuters: Shanghai IPO timetable and share count, 30 July 2026.
Shanghai Stock Exchange: regulatory approval, 6 July 2026.
Unitree Robotics: STAR Market draft prospectus, March 2026.
Shanghai Stock Exchange / Global Times: revenue, profit and fundraising plan, 26 May 2026.
Unitree: company statement on 2025 shipments, 29 January 2026.
Associated Press: US restrictions on foreign humanoid and quadruped robots, 29 July 2026.

Notice: This article is for information only and is not investment advice or a recommendation to buy or sell securities. Alpha Bionic independently expanded and analysed the supplied report using exchange documents and linked sources.

Bewerte den Beitrag hier!

[Total: 0 Average: 0]

Nico Nuss

Website

Author Nico Nuss has been working on mobile computing and automation software since 2001. Drawing on his experience and strong interest in future technologies, he focuses on robotics and AI.